Suppr超能文献

疫苗和乙型肝炎免疫球蛋白诱导的乙型肝炎病毒表面抗原逃逸突变

Vaccine- and hepatitis B immune globulin-induced escape mutations of hepatitis B virus surface antigen.

作者信息

Cooreman M P, Leroux-Roels G, Paulij W P

机构信息

Department of Gastroenterology and Hepatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.

出版信息

J Biomed Sci. 2001 May-Jun;8(3):237-47. doi: 10.1007/BF02256597.

Abstract

Hepatitis B virus surface antigen (HBsAg) vaccination has been shown to be effective in preventing hepatitis B virus (HBV) infection. The protection is based on the induction of anti-HBs antibodies against a major cluster of antigenic epitopes of HBsAg, defined as the 'a' determinant region of small HBsAg. Prophylaxis of recurrent HBV infection in patients who have undergone liver transplantation for hepatitis B-related end-stage liver disease is achieved by the administration of hepatitis B immune globulins (HBIg) derived from HBsAg-vaccinated subjects. The anti-HBs-mediated immune pressure on HBV, however, seems to go along with the emergence and/or selection of immune escape HBV mutants that enable viral persistence in spite of adequate antibody titers. These HBsAg escape mutants harbor single or double point mutations that may significantly alter the immunological characteristics of HBsAg. Most escape mutations that influence HBsAg recognition by anti-HBs antibodies are located in the second 'a' determinant loop. Notably, HBsAg with an arginine replacement for glycine at amino acid 145 is considered the quintessential immune escape mutant because it has been isolated consistently in clinical samples of HBIg-treated individuals and vaccinated infants of chronically infected mothers. Direct binding studies with monoclonal antibodies demonstrated a more dramatic impact of this mutation on anti-HBs antibody recognition, compared with other point mutations in this antigenic domain. The clinical and epidemiological significance of these emerging HBsAg mutants will be a matter of research for years to come, especially as data available so far document that these mutants are viable and infectious strains. Strategies for vaccination programs and posttransplantation prophylaxis of recurrent hepatitis need to be developed that may prevent immune escape mutant HBV from spreading and to prevent these strains from becoming dominant during the next decennia.

摘要

乙肝病毒表面抗原(HBsAg)疫苗接种已被证明可有效预防乙肝病毒(HBV)感染。这种保护作用基于诱导产生针对HBsAg主要抗原表位簇的抗-HBs抗体,该表位簇被定义为小分子HBsAg的“a”决定簇区域。对于因乙肝相关终末期肝病接受肝移植的患者,通过给予来自接种过HBsAg疫苗个体的乙肝免疫球蛋白(HBIg)来预防HBV复发感染。然而,抗-HBs介导的对HBV的免疫压力似乎伴随着免疫逃逸HBV突变体的出现和/或选择,这些突变体使病毒能够在抗体滴度足够的情况下持续存在。这些HBsAg逃逸突变体携带单点或双点突变,可能会显著改变HBsAg的免疫学特性。大多数影响抗-HBs抗体识别HBsAg的逃逸突变位于第二个“a”决定簇环。值得注意的是,在氨基酸145处精氨酸取代甘氨酸的HBsAg被认为是典型的免疫逃逸突变体,因为它在接受HBIg治疗的个体以及慢性感染母亲的接种婴儿的临床样本中持续被分离出来。与该抗原结构域中的其他点突变相比,单克隆抗体的直接结合研究表明该突变对抗-HBs抗体识别的影响更为显著。这些新出现的HBsAg突变体的临床和流行病学意义将是未来数年的研究课题,特别是因为目前可得的数据表明这些突变体是有活力的感染性毒株。需要制定疫苗接种计划策略以及肝移植后复发性肝炎的预防措施,以防止免疫逃逸突变体HBV传播,并防止这些毒株在未来十年内成为优势毒株。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验